Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
SHSE:600062's Debt-to-Equity is ranked better than 72.72% of 810
companies
in the Drug Manufacturers industry
Industry Median: 0.28
vs SHSE:600062: 0.10
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
China Resources Double-Crane Pharmaceutical Co Debt-to-Equity Related Terms
China Resources Double-Crane Pharmaceutical Co Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Resources Double-Crane Pharmaceutical Co Debt-to-Equity Chart
China Resources Double-Crane Pharmaceutical Co Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, China Resources Double-Crane Pharmaceutical Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Resources Double-Crane Pharmaceutical Co Debt-to-Equity vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Resources Double-Crane Pharmaceutical Co (SHSE:600062) has a Debt-to-Equity of 0.10 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on China Resources Double-Crane Pharmaceutical Co and its competitors. This is 400% above median its historical median of 0.02. Over the past decade, China Resources Double-Crane Pharmaceutical Co's Debt-to-Equity has ranged from 0.01 to 0.14. According to the industry distribution chart, China Resources Double-Crane Pharmaceutical Co ranks #221 out of 810 companies in the Drug Manufacturers industry, placing it in the top 27.3%.
Is China Resources Double-Crane Pharmaceutical Co's Debt-to-Equity too high?
China Resources Double-Crane Pharmaceutical Co's current Debt-to-Equity of 0.10 is 400% above median its 10-year median of 0.02. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.14. The Drug Manufacturers industry median Debt-to-Equity is 0.28. China Resources Double-Crane Pharmaceutical Co's value of 0.10 is 64.3% below this industry median. Based on the distribution chart, China Resources Double-Crane Pharmaceutical Co ranks #221 out of 810 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, China Resources Double-Crane Pharmaceutical Co has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does China Resources Double-Crane Pharmaceutical Co's Debt-to-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, China Resources Double-Crane Pharmaceutical Co ranks #221 out of 810 companies for Debt-to-Equity. This puts China Resources Double-Crane Pharmaceutical Co in the upper half of its industry. The industry median Debt-to-Equity is 0.28. China Resources Double-Crane Pharmaceutical Co's value of 0.10 is 64.3% below this benchmark. Historically, China Resources Double-Crane Pharmaceutical Co's own Debt-to-Equity has ranged from 0.01 to 0.14 over the past decade. While the company's 10-year median is 0.02 vs. the industry median of 0.28, China Resources Double-Crane Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.28, based on 810 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Resources Double-Crane Pharmaceutical Co's current Debt-to-Equity of 0.10 is 64.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on China Resources Double-Crane Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Resources Double-Crane Pharmaceutical Co's current Debt-to-Equity is 0.10, which is 400% above median its own 10-year median of 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Resources Double-Crane Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, China Resources Double-Crane Pharmaceutical Co (SHSE:600062) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥18.78, compared to a current price of ¥16.02 — trading 14.7% below its estimated fair value. The current Debt-to-Equity is 0.10, which is 400% above median its 10-year median of 0.02 and 64.3% below the Drug Manufacturers industry median of 0.28. China Resources Double-Crane Pharmaceutical Co's overall GF Score™ is 91/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For China Resources Double-Crane Pharmaceutical Co (SHSE:600062), the current Debt-to-Equity is 0.10 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Resources Double-Crane Pharmaceutical Co (SHSE:600062) Overvalued in 2026?
Based on GuruFocus' analysis, China Resources Double-Crane Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥16.02 is trading 14.7% below its estimated GF Value™ of ¥18.78.
GuruFocus considers China Resources Double-Crane Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for SHSE:600062:
Debt-to-Equity: 0.10 (400% above median its 10-year median of 0.02)
GF Value™: ¥18.78 vs. price of ¥16.02 (14.7% below fair value)
Industry Position: 64.3% below the Drug Manufacturers median (#221 of 810)
No single metric tells the full story. See the SHSE:600062 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Resources Double-Crane Pharmaceutical Co Ltd is a China-based pharmaceutical company. It is engaged in developing, manufacturing and marketing a variety of medical products. The company's products cover different fields such as infusion field, cardiovascular and cerebrovascular fields, pediatrics, endocrine field and other areas.
91GF Score
Get the complete analysis for SHSE:600062
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600062 has been successfully added to your 
